Oxford BioMedica Announces Top-Line Results From Six Month Follow-Up of Third Patient Cohort in Prosavin® Phase I/II Study in Parkinson’s Disease
Oxford, UK – 3 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II…